Combined 18F-Fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: Results of an international multicenter trial

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 176-183

  Iagaru, Andrei ^a,f   Mittra, Erik ^a   Mosci, Camila ^a   Dick, David W ^a   Sathekge, Mike ^b   Prakash, Vineet ^c   Iyer, Victor ^c   Lapa, Paula ^d   Isidoro, Jorge ^d   De Lima, Joao M ^d   Gambhir, Sanjiv Sam ^e  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e STANFORD UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG; 18F ; Cancer; PET CT

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; GLUCOSE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DOSIMETRY; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; BONE; BONE TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; IMAGE PROCESSING; INTERNATIONAL COOPERATION; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; NUCLEAR MEDICINE; ONCOLOGY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERNATIONAL COOPERATION; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NUCLEAR MEDICINE; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

MLCS; MLOWN;

EID: 84873540075     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.108803     Document Type: Article

References (33)

1. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the national oncologic PET registry. J Clin Oncol. 2008;26:2155-2161.
2. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics. 2004;24:523-543.
3. Podoloff DA, Ball D, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009;7(suppl 2):S1-S26.
4. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27-37.
5. 18F bone scan lesions. Radiology. 1974;112:369-372.
6. 18F-fluoride PET/CT. J Nucl Med. 2004;45: 272-278.
7. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
8. 18Ffluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813-1820.
9. 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilotphase study. J Nucl Med. 2009;50:501-505.
10. Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging. 2010;37:1490-1498.
11. Shamim SA, Kumar R, Shandal V, et al. FDG PET/CT evaluation of treatment response in patients with recurrent colorectal cancer. Clin Nucl Med. 2011;36: 11-16.
12. Onishi Y, Ohno Y, Koyama H, et al. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Eur J Radiol. 2011;79:473-479.
13. 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases: comparison of qualitative visual and semiquantitative analysis. Nuklearmedizin. 2004;43:91-101.
14. Gallowitsch H-J, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positronemission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38:250-256.
15. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
16. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311-317.
17. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
18. Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:408-415.
19. 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-259.
20. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168-176.
21. 223Ra-chloride (Alpharadin). EJNMMI Research. 2011;1:4.
22. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol. 2003;32:201-208.
23. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-142.
24. Jadvar H, Pinski J, Conti P. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003;10:1485-1488.
25. 18F-FDG-PET/CT. Ann Nucl Med. 2012;26: 138-145.
26. 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16: 6093-6099.
27. Hoegerle S, Juengling F, Otte A, et al. Combined FDG and [F-18]fluoride wholebody PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209: 253-258.
28. Richmond K, McLean N, Rold T, et al. Optimizing a F-18 NaF and FDG cocktail as a preclinical cancer screening tool for molecular imaging. J Nucl Med. 2011;52(suppl):517P.
29. Kazama T, Swanston N, Podoloff D, Macapinlac H. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406-1411.
30. Surti S, Scheuermann J, El Fakhri G, et al. Impact of time-of-flight PET on whole-body oncologic studies: a human observer lesion detection and localization study. J Nucl Med. 2011;52:712-719.
31. Pichler BJ, Judenhofer M, Wehrl H. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18:1077-1086.
32. Zaidi H, Ojha N, Morich M, et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol. 2011;56:3091-3106.
33. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.